In this real-world setting, patients who were treated with semaglutide 2.4 mg and tirzepatide had a mean weight loss of 14.1% and 16.5% at 1 year, respectively, which represents a clinically meaningful weight loss with both therapies when used in patients with overweight or obesity and without T2DM [20]
A once-weekly injection delivering that level of pain relief in patients who may not yet need surgery is a potentially transformative finding
Moreover, in in vivo setting, liraglutide promoted M2 macrophage phenotype by the expression of M2 macrophage markers, Arg-1 and CD163, which suggested liraglutide inhibition of atherosclerosis development
AOD-9604: Accelerating Weight Loss Through Peptide Therapy What is AOD-9604
In an 8-week study there was no difference between those who took L-carnitine and those who did not 12
No pediatric indication or safety data